Introduction: Adequate intraoperative lymph node sampling is a fundamental part of lung cancer surgery, but adherence to standards is not well known. This study sought to measure the adequacy of intraoperative lymph node sampling at a regional Thoracic Surgery Centre and a tertiary lung cancer center in the United Kingdom.
Methods: This retrospective study analyzed the pathological reports from NSCLC resections over the 4-year period 2011-2014. Adequacy of sampling was assessed against International Association for the Study of Lung Cancer recommendations of at least three mediastinal lymph node stations: station 7 in all patients, station 5 or 6 in left upper lobe tumors, and station 9 in lower lobe tumors. The influence of clinical variables (age, tumor T stage, type of surgery, and laterality) on adequacy of sampling and the effect of adequacy on overall survival were also assessed.
Results: A total of 1301 NSCLC resections were performed from January 11, 2011, to December 31, 2014. Adequate intraoperative lymph node sampling increased significantly from 14% (22 of 160) in 2011 to 53% (206 of 390) in 2014 (p ¼ 0.001). Secondary analysis of clinical variables also revealed that patients with T1a or T4 tumors, those undergoing sublobar resections, those undergoing video-assisted thoracic surgery resections, and those undergoing left-sided resections have significantly higher rates of inadequate lymph node sampling. Overall, there was no statistically significant difference in survival between patients with adequate versus inadequate intraoperative lymph node sampling or when survival was stratified according to overall stage. There was worse survival in inadequate sampling for patients with pN2 disease than for patients with pN2 disease and adequate sampling.
Introduction
Adequate intraoperative lymph node (LN) sampling is a fundamental part of lung cancer surgery, informing prognosis through accurate staging, indications for adjuvant treatment, and the intensity of surveillance programs after treatment. The International Association for the Study of Lung Cancer (IASLC) has defined adequate LN sampling as at least three mediastinal LN stations (station 7 in all cases, station 5 or 6 with left upper lobe tumors, and station 9 with lower lobe tumors), and the sampling of at least three hilar LN stations is also recommended. 1 However, adherence to this key performance measure across the United Kingdom is not widely known at a national, regional, or individual-center level. In addition, an acceptable rate of adequacy has yet to be defined.
The University Hospital of South Manchester (UHSM) is a regional thoracic oncology center in the Northwest of England and the thoracic surgical center for 10 National Health Service trusts. Surgical resection is the recommended treatment for stage I, II, and selected cases of stage III NSCLC, assuming adequate physiological assessment and patient preference.
2 Adjuvant chemotherapy is recommended in line with international guidelines; stage I with the primary tumor larger than 4 cm and all cases of stage II and III.
3 Systematic preoperative nodal staging is performed with physician-led endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration delivered at four centers across the network, including UHSM, in line with international and national standards. [4] [5] [6] Mediastinoscopy is reserved for selected cases of negative EBUS-guided transbronchial needle aspiration at the discretion of local multidisciplinary teams. The regional cancer network is responsible for the diagnosis and treatment of more than 2000 patients with lung cancer annually. The primary aim of this study was to examine the adequacy of intraoperative LN sampling at UHSM using the standards set out by the IASLC staging manual. Secondary aims were to examine which factors may influence adequacy and the relationship between adequacy and overall survival.
Materials and Methods
A retrospective review of the pathological reports for all NSCLC surgical resections at UHSM between January 1, 2011, and December 31, 2014, was undertaken. Cases of SCLC, well-differentiated neuroendocrine tumors (typical and atypical carcinoid), and other metastatic nonprimary lung tumors were excluded. No cases received induction therapy before surgery. In cases of synchronous primary tumors, the highest stage tumor was considered the index lesion for assessing LN sampling. Lung cancer resection specimens are reported in line with the minimum data set defined by the Royal College of Pathology and contain a record of all LN stations sampled intraoperatively and the histological findings from these LNs. Nodal sampling was classified as adequate if at least three mediastinal LN stations were sampled (station 7 in all cases, station 5 or 6 with left upper lobe tumors, and station 9 with lower lobe tumors) in accordance with IASLC standards. 1 Hilar nodal sampling was not included, as it was not possible to ascertain how many hilar LNs had been sampled from the pathology report (hilar nodes are often removed within the resection sample and not commented on separately). At UHSM all lung cancer resections are performed by five dedicated thoracic surgeons. No procedures are performed by general or cardiac surgeons. Data were collected on annual basis from 2012 to 2015 where the previous calendar year's data were added to a database (covering the period 2011-2014). Annual performance with regard to the adequacy of LN sampling was discussed internally at UHSM. The survival analysis was performed when a minimum of 2 years' follow-up had been undertaken for the final cohort of 2014. In terms of preoperative staging, the regional guidelines recommend EBUS staging in any patients with a central tumor, or nodal enlargement/fludeoxyglucose avidity at either the hilum or mediastinum on computed tomography or positron emission tomography scan. Peripheral tumors with normal hilum/mediastinum on computed tomography and positron emission tomography scan will proceed directly to treatment without pathological nodal staging. Ethical approval was not required given the retrospective, nonexperimental nature of this study looking at service performance audited against an international standard.
The influence of clinical variables on adequacy of LN sampling was investigated. Variables analyzed included patient age, tumor T stage, type of surgery (pneumonectomy, lobectomy/bilobectomy, or sublobar and thoracotomy versus video-assisted thoracic surgery [VATS] ) and laterality (right or left). Survival data were obtained through national death registry searches. Kaplan-Meier analyses were used to estimate the survival functions for adequacy stratified by N status and overall stage. Survival time was calculated from date of operation to date of death or last follow-up date to December 2016, ensuring a minimum of 2 years' follow-up for survival data. Log-rank tests were used to compare survival curves between patient groups. All summaries, graphs, and analyses were produced using IBM SPSS software, version 20 (IBM, Inc., Armonk, NY). 
Age and Adequacy
The median age of patients with adequate LN sampling was 68 (interquartile range 62-74, range 43-86). For patients with inadequate sampling, the median age was 68 (interquartile range 63-74, range 60-87). There was no statistically significant difference between the ages in the two groups (p ¼ 0.54).
T-Stage and Adequacy
There was a statistically significant relationship between adequacy and T stage (p ¼ 0.035). The chisquare test for linear trend was not significant (p ¼ 0.79), so the relationship was not simply that as T-stage increases, the proportion of patients with adequate nodal sampling increases. In T1a and T4 tumors a greater proportion of the patients had inadequate nodal sampling compared with those with T2 tumors (Fig. 1) . Of the 32 T4 tumors, one was a great vessel invasion and 31 were satellite tumors in an ipsilateral lobe. The great vessel invasion was adequately sampled, and five of the 31 satellite tumors (16.1%) were adequately sampled.
Type of Surgery and Adequacy
The proportions of patients with adequate LN sampling undergoing pneumonectomy, lobectomy/ bilobectomy, and sublobar resection were 45% (46 of 102), 38% (399 of 1060), and 18% (25 of 139), respectively. There is a statistically significant relationship between adequacy of nodal sampling and surgery type (p < 0.001). The percentage of T1a tumors in sublobar resection was 43.2% (60 of 139), whereas this percentage was 19.0% of lobectomy patients (200 of 1055) and 6.9% of pneumonectomy patients (seven of 102). For T1b tumors, the percentage was 12.2% of sublobar patients (17 of 139), 16.9% of lobectomy patients (178 of 1055), and 6.9% of pneumonectomy patients (seven of 102). The vast majority of resections during this study period were performed by thoracotomy (1209 of 1290 [94%], excluding missing data) compared with a VATS approach. There was a statistically significant relationship between type of surgery and adequacy of LN sampling (p < 0.001). The percentage of patients with adequate LN sampling who had a thoracotomy was 38.1% (461 of 1209) and for VATS the percentage was 2.5% (two of 81).
Operation Side and Adequacy
In patients undergoing left-sided resections the rate of adequate intraoperative LN sampling was 25% compared with 44% in those undergoing right-sided resections. There was a statistically significant relationship between 
Survival and Adequacy
Overall, there was no statistically significant difference in survival between patients with adequate intraoperative LN sampling and those with inadequate sampling (log-rank p ¼ 0.61 [ Fig. 2]) . However, when stratified according to pN status, inadequate LN sampling was associated with worse survival in patients with pN2 disease (median survival time with pN2 was 1134 days with adequate sampling [95% confidence interval: 904-1364] versus 798 days with inadequate sampling [95% confidence interval: 543-1053]), although this difference did not reach statistical significance. Survival was also analyzed according to overall stage, and inadequate LN sampling was not associated with survival in patients with stage I (log-rank p ¼ 0.49), stage II (log-rank p ¼ 0.65), or stage III (log-rank p ¼ 0.74) NSCLC (see Fig. 3 ).
Discussion
There has been a significant improvement in LN sampling over the 4 years of this study such that 53% of patients undergoing NSCLC surgery at UHSM in 2014 had adequate intraoperative LN sampling. This improvement occurred at a time of significant increase in the volume of lung cancer surgery. Further improvement is required to meet the standards as defined by the IASLC, but what constitutes an "acceptable" level of adequacy remains to be defined at a national level. Secondary analysis has also revealed that patients with a low or high T-stage (T1a or T4), those undergoing sublobar resections, those undergoing VATS resection, and those undergoing left-sided resections have significantly higher rates of inadequate LN sampling. These represent further focus areas to drive improvements and have formed part of the feedback to the thoracic oncology team at UHSM. There were only a limited number of VATS procedures performed during this study with a very poor rate of adequate LN sampling. The development of a robust VATS program and adherence to standards of LN sampling during this technique is a focus for this surgical group and future analysis.
Although this study was designed with a heavy focus on mediastinal nodal sampling, there is a weakness with the lack of assessment of hilar node sampling. Although some peribronchial nodes were removed with the resected lung and were difficult to encompass in the analysis, stations 10 and 11 are removed en bloc and could be assessed within an analysis such as this. We acknowledge this as a weakness of the study and will be amending the data collection for ongoing analysis.
There are several potential contributing factors to the improvement in LN sampling over the study period. The very process of performance monitoring is a powerful driver of improved standards, as is well demonstrated in large-scale projects such as the National Lung Cancer Audit in the United Kingdom. This data collection process began in 2012, with each year's data added at annual time points until a sizeable cohort with appropriate minimum follow-up was achieved. Internally, the annual performance data were fed back to the surgical team. This performance monitoring, led by the respiratory/pulmonology department external to the thoracic surgery directorate, is an inherent motivation to drive up standards. Furthermore, this project is one of several nodal staging performance monitoring projects that includes EBUS performance across the Manchester Cancer Network. 7 We have learned that such projects are a vital component of service delivery. We have found that we are never as good as we think we are when the raw data are analyzed, and this focuses the team on specific areas where improvements can be delivered and monitored. A process of open publication of results is a key component of this and is supported by the broad thoracic oncology team at UHSM to encourage similar approaches in other centers and to provide benchmarking data for performance.
The analysis of survival data has provided interesting results, but there are challenges in the interpretation of these results. There is no difference in overall survival between those patients with adequate versus those with inadequate intraoperative nodal sampling with a followup period of between 2 and 5 years for all patients. This remains the case when survival is stratified by overall stage. However, patients with the longest follow-up from 2011 represent the smallest proportion of this study population, whereas the highest volume of surgery occurred in 2013 and 2014, which carry the shortest period of follow-up (160 resections in 2011 versus 390 in 2014). Therefore, a more definitive conclusion would require a longer follow-up period. In the poorestprognosis group (pN2), where survival differences are likely to be detected at an earlier time frame, there is a survival difference according to adequacy of LN sampling (1134 days versus 798 days). We postulate that this is due to the effect of potential R1 resection and residual N2 disease. Furthermore, most of the tumors in this study were small, for which the probability of nodal metastases is low. Therefore, any impact of inadequate LN sampling will be harder to detect given that the vast majority of patients will be stage pN0 regardless of adequacy of sampling. Tumors measuring less than 3 cm (T1a and T1b) constituted 35% of the tumors resected in this study (457 of 1301) and tumors measuring <4cm (T1a, T1b and T2a) constituted 70% (907 of 1301). Although no effect on survival has been found through inadequate LN sampling, the limitations of this analysis are significant and we urge caution in interpretation of this finding. Clearly, these results cannot be used as a justification for not pursuing a comprehensive intraoperative LN sampling in all lung cancer resections.
In conclusion, this study provides a much-needed benchmark of current thoracic surgical practice in lung cancer in the United Kingdom. Furthermore, it provides important granularity to facilitate improvements in the adequacy of intraoperative LN staging. Ongoing annual monitoring of this key metric is planned for local quality assurance and could be considered at a national level through the Society of Cardiothoracic Surgeons or the National Lung Cancer Audit.
